GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Jiangzhong Pharmaceutical Co Ltd (SHSE:600750) » Definitions » Total Assets

Jiangzhong Pharmaceutical Co (SHSE:600750) Total Assets : ¥6,127 Mil (As of Sep. 2024)


View and export this data going back to 1996. Start your Free Trial

What is Jiangzhong Pharmaceutical Co Total Assets?

Jiangzhong Pharmaceutical Co's Total Assets for the quarter that ended in Sep. 2024 was ¥6,127 Mil.

During the past 12 months, Jiangzhong Pharmaceutical Co's average Total Assets Growth Rate was 51.80% per year. During the past 3 years, the average Total Assets Growth Rate was 18.60% per year. During the past 5 years, the average Total Assets Growth Rate was 9.00% per year. During the past 10 years, the average Total Assets Growth Rate was 5.90% per year.

During the past 13 years, Jiangzhong Pharmaceutical Co's highest 3-Year average Total Assets Growth Rate was 63.30%. The lowest was -1.70%. And the median was 10.20%.

Total Assets is connected with ROA %. Jiangzhong Pharmaceutical Co's annualized ROA % for the quarter that ended in Sep. 2024 was 9.49%. Total Assets is also linked to Revenue through Asset Turnover. Jiangzhong Pharmaceutical Co's Asset Turnover for the quarter that ended in Sep. 2024 was 0.13.


Jiangzhong Pharmaceutical Co Total Assets Historical Data

The historical data trend for Jiangzhong Pharmaceutical Co's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jiangzhong Pharmaceutical Co Total Assets Chart

Jiangzhong Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4,759.19 4,923.87 5,997.60 6,276.25 6,128.54

Jiangzhong Pharmaceutical Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6,239.72 6,128.54 6,527.12 6,144.18 6,126.75

Jiangzhong Pharmaceutical Co Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Jiangzhong Pharmaceutical Co's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets=Total Equity (A: Dec. 2023 )+Total Liabilities (A: Dec. 2023 )
=4475.106+1653.437
=6,129

Jiangzhong Pharmaceutical Co's Total Assets for the quarter that ended in Sep. 2024 is calculated as

Total Assets=Total Equity (Q: Sep. 2024 )+Total Liabilities (Q: Sep. 2024 )
=4231.994+1894.758
=6,127

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jiangzhong Pharmaceutical Co  (SHSE:600750) Total Assets Explanation

Total Assets is connected with ROA %.

Jiangzhong Pharmaceutical Co's annualized ROA % for the quarter that ended in Sep. 2024 is

ROA %=Net Income (Q: Sep. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Sep. 2024 ))/ count )
=582.348/( (6144.179+6126.752)/ 2 )
=582.348/6135.4655
=9.49 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Jiangzhong Pharmaceutical Co's Asset Turnover for the quarter that ended in Sep. 2024 is

Asset Turnover
=Revenue (Q: Sep. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Sep. 2024 ))/ count )
=799.352/( (6144.179+6126.752)/ 2 )
=799.352/6135.4655
=0.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Jiangzhong Pharmaceutical Co Total Assets Related Terms

Thank you for viewing the detailed overview of Jiangzhong Pharmaceutical Co's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Jiangzhong Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
No. 788, Torch Avenue, High-tech Zone, Jiangxi Province, Nanchang, CHN, 330096
Jiangzhong Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is mainly engaged in producing and selling Chinese traditional medicines, healthcare food, and functional foods.
Executives
Lu Xiao Qing Director
Xiao Wen Bin Director
Zhang Xi He Director
Cai Xin Ping Director
Li Xiao Jun Director
Tian Yong Jing Director
Liu Wen Jun Director
Xing Jian Director
Xu Yong Qian Director
Liu Wei Quan Director

Jiangzhong Pharmaceutical Co Headlines

No Headlines